Abstract: The invention relates to Crystal Hydrate Form VI of Dabrafenib and preparation method thereof, wherein Crystal Hydrate Form VI of Dabrafenib has the advantage of being more stable at room temperature or in aqueous systems, and has low hygroscopicity, and thus is more suitable for a wet granulation process or being prepared into a suspension; and the present invention also relates to a pharmaceutical composition and formulations comprising Crystal Hydrate Form VI of Dabrafenib, and their use in the treatment of Raf family kinase-related diseases.

Abstract: The present invention relates to a new crystalline forms of the inhibitor, 5-fluoro-3-phenyl-2-[(S)-1-(9H-purin-6-ylamino)-propyl]-3H-quinazoline-4-one; the new crystalline form, compared to known forms, has one or more improved properties. The present invention also relates to a method for preparing a new crystalline form of 5-fluoro-3-phenyl-2-[(S)-1-(9H-purin-6-ylamino)-propyl]-3H-quinazolin-4-one, a pharmaceutical composition thereof and a use thereof in preparation of a pharmaceutical for the treatment and/or prevention of diseases such as chronic lymphocytic leukemia and indolent non-Hodgkin's lymphoma.

Abstract: Disclosed are a novel crystal form of Dabrafenib mesylate and preparation method thereof. The novel crystal form of the present invention is more stable in water or an aqueous system, and has greater solubility and dissolution in water, thus having better stability and bioavailability compared with the existing crystal forms.

Abstract: The present invention relates to a crystalline Form M of trametinib dimethyl sulfoxide solvate. Comparing with the prior art, Form M is a more stable crystalline form with better particle size distribution and good flowability and is non-hygroscopic. Therefore, it is more suitable for formulation. The present invention also relates to pharmaceutical compositions thereof, methods of making and using thereof.

Abstract: The invention relates to a new crystal form of dabrafenib and preparation method thereof. With respect to known crystal forms, the new crystal form has the advantage of being more stable at room temperature or in aqueous systems, and has low hygroscopicity, and thus is more suitable for a wet granulation process or being prepared into a suspension. The present invention also relates to a pharmaceutical composition and formulations comprising the new crystal form, and their use in the treatment of Raf family kinase-related diseases.

Abstract: The present invention provides an LNG production system and method with improved refrigeration. The refrigeration is achieved by a refrigeration device comprising a plurality of refrigerant compressors (11, 13, 15, 17) configured into a series arrangement to perform multi-stage compressions of a refrigerant, a plurality of aftercoolers (12, 14, 16, 18) each of which being coupled to each of the plurality of refrigerant compressors to cool the compressed refrigerant, a plurality of turboexpanders (19, 20) coupled to the last aftercooler (18) and configured into a series configuration to perform multi-stage expansions of the compressed refrigerant, and a plurality of refrigerant heat exchange means (33, 34) coupled to both the first (11) of the plurality of refrigerant compressors and the last (20) of the plurality of turboexpanders, so that all components form a close refrigeration cycle.

Abstract: The present invention relates to a crystalline Form M of trametinib dimethyl sulfoxide solvate. Comparing with the prior art, Form M is a more stable crystalline form with better particle size distribution and good flowability and is non-hygroscopic. Therefore, it is more suitable for formulation. The present invention also relates to pharmaceutical compositions thereof, methods of making and using thereof.

Abstract: Embodiments of the present invention provide a process for liquefaction of a natural gas. The process includes cooling the natural gas with a first refrigerant provided by a first cooling system and cooling the natural gas with a second refrigerant provided by a second cooling system. The second cooling system is a single phase cooling system. The first and second cooling systems operate independently from each other. The second refrigerant is cooled with the first refrigerant so that the cooling capacity of the second refrigerant and the second cooling system is increased.

Abstract: A surface with superhydrophobic and hydrophilic or superhydrophilic regions can be made. The hydrophilic or superhydrophilic regions can selective collect water on the surface.

Abstract: A natural gas liquefaction process suited for offshore liquefaction of natural gas produced in association with oil production is described.

Abstract: A surface with superhydrophobic and hydrophilic or superhydrophilic regions can be made. The hydrophilic or superhydrophilic regions can selective collect water on the surface.